Seletalisib

1362850-20-1

C23H14ClF3N6O

DMSO : >= 83.3 mg/mL (172.52 mM)

PI3K/Akt/mTOR

Seletalisib (UCB5857) is potent and selective PI3Kdelta inhibitor with an IC₅₀ of 12 nM. IC50 & Target: IC50: 12 nM (PI3Kdelta)^[1] In Vitro: Seletalisib is a potent, ATP-competitive and highly selective PI3Kdelta inhibitor able to block AKT phosphorylation following activation of the BCR in a B-cell line. Seletalisib inhibits N-formyl peptides (fMLP)-stimulated but not phorbol myristate acetate (PMA)-stimulated superoxide release from human neutrophils consistent with a PI3Kdelta-specific activity. No indications of cytotoxicity are observed in PBMCs or other cell types treated with seletalisib. seletalisib blocks human T-cell production of several cytokines from activated T-cells. Seletalisib inhibits T-cell differentiation to Th1, Th2, and Th17 subtypes. Additionally, seletalisib inhibits B-cell proliferation and cytokine release. In human whole blood assays, seletalisib inhibits CD69 expression upon B-cell activation and anti-IgE-mediated basophil degranulation^[1]. In Vivo: Seletalisib significantly inhibits IL-2 release following TCR stimulation in the rat. The inhibition is observed at all tested doses of seletalisib with almost complete inhibition reached at dose levels >=1 mg/kg. Seletalisib has potent in vivo effects with an estimated IC₅₀ value of <10 nM^[1].